The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Picked up a few more at Ā£1.55 today, happy with that. Just shy of 30k shares now . I hope Iām right been invested for years only taken it seriously the last 3 or 4 . Hope for our sakes and the health of others it delivers! GLA
https://twitter.com/jebkeiper/status/1568450021783207937?s=21&t=PBMpPDHUx7DoNFxIb2WBZg
Surely with all these developments, whatever your standpoint, now is the time to be pushing forward with this and at the same time enhancing the awareness of SAR and the other great prospects. It was months ago that this was revealed to be the case and throughout the pandemic Dex has been lauded for saving hundreds and thousands of lives. Surely there must be imminent developments in this area to improve treatments and save lives and as a consequence further raise SAR profile etc GLA our time is coming
The science hasnāt changed and I remain positive although a little frustrated, love the info and research on here. I wonder given the previous positive tone, tweets (in to clinic, honoured, better than dex etc) whether the slipped timeline could be associated with on going negotiations. We were close to go with CTA in an indication of our choosing and into P1 from there but could it be at the behest of a partner or suitor that things are delayed to allow for a different indication to be targeted?? The only way of doing so without letting the cat out of the bag could be to buy time by using the delays experienced all of a sudden!! I know SAR have a track record of missed timelines but on this occasion perhaps it is different and things could change very quickly if this is the case with news drop at anytime . Sincerely hope so. Sitting on 1.39m shares and hoping/expecting great things. Happy to be corrected, if itās too much wishful thinking GLA
Results updated bang on time - indicate better than Dexamethasone, a drug hailed world wide for its benefits in saving in excess of a million lives! Similar to Baricitinib but that has Black box warnings of severe side effects therefore implication we are superior. HNWIs invest and continue to do so to the tune of Ā£3.5m that is some endorsement. Since this fantastic news the BOD and Parker who previously appeared to be barely able to contain their excitement with tweets and comments in presentations etc have revealed and commented or retweeted not a thing when they have had many opportunities to do so - this to me is indication enough that there are big things ahead, imminently!! Add to this no shares sold by John or Tim at various highs, the warrant prices and no speeding tickets on the previous spike screams to me that this is going higher, much, much higher. INHO, GLA come on SAR!!!
Have a good day all.
Had an apartment in Javea between arenal and old town 20 years ago fab place and climate . Hot hot hot in summer thoā played a few rounds la sella not very well as ever but very enjoyable. Hope SAR come good and can do it again
In view of the brilliant recent RNS - the radio silence, in my view, speaks volumes. As ever no parading or showboating from SAR - reread RNS and ask yourself why? Iām Very optimistic and a great base price to push on from once further news drops!! GLA come on sar !
Aj from biotrinity presentation
JAK2 and JAK3 inhibition associated with the FDA āblack boxā warnings for serious infections, lymphoma and thrombosis issued to JAK1/JAK3 inhibitor Xeljanz (tofacitinib) and JAK1/JAK2 inhibitor Olumiant (baricitinib)
Not forgetting H7 100 day mission
In response, an independent group, the pandemic preparedness partnership, was established to advise the UK G7 Presidency on how to develop and deploy safe, effective diagnostics, therapeutics, and vaccines within the first 100 days of a pandemic. This is predicated on an effective global surveillance system to identify a pandemic threat quickly. Then, alongside crucial non-pharmaceutical interventions like social distancing, contact tracing and PPE, rapid deployment of effective diagnostics, therapeutics and vaccines can save countless lives.
For these reasons, the pandemic preparedness partnership has set out the 100 Days Mission for developing safe, effective diagnostics, therapeutics and vaccines at scale
Also from slides
JAK2 and JAK3 inhibition associated with the FDA āblack boxā warnings for serious infections, lymphoma and thrombosis issued to JAK1/JAK3 inhibitor Xeljanz (tofacitinib) and JAK1/JAK2 inhibitor Olumiant (baricitinib)
SDC-1801 and SDC-1802
ā¢ Potent & selective inhibitors of TYK2 and JAK1 kinases
ā¢ Oral twice-daily dosing in mice, potential for once-daily dosing in humans
ā¢ Favourable selectivity profile vs JAK2 and JAK3 kinases (cf tofacitinib, baricitinib)
ā¢ Potential to treat the ācytokine stormā immune system over-reaction that can be fatal in Covid-19 patients
Taken from RNS - as we near end of June and on schedule -exciting times ahead
GLA
The UKRI-funded Covid-19 research project for SDC-1801 continues on schedule with the experimental phases finishing by the end of June and the data analysis to complete shortly thereafter. The Company will provide a further update once the relevant data are available.
Focus still fully on COVID and access to Agile funding in the immediate term - given the potential for funding a sensible and obvious play especially considering the urgency in a pandemic
1801 will then ride the coattails through to CTA
Iām just relieved itās still there and not been deleted- was concerned heād gone off script. Gives me confidence that it is supported- in itself it is very positive but my take is if SAR happy for it to stay - even better !! GLALTH our time is coming I hope
Not much new news but all still in play as we know . Good news on the potential further progress 737 shortly. My take thoā was that I thought John sounded quietly confident or at least positive regarding Covid potential - I think they know they are on the right track and have a v good opportunity to put something special out there. I sincerely hope so. GLALTHS
I was concerned initially by the Nimbus press release but I take it you see this as a positive for raising the profile not taking away market share??
Best position we have been in for a long time with news due on multiple fronts - I hope it comes good for us all after the patience and loyalty shown by so many for so long GLA